Key result
Low-dose prasugrel for flow diverter treatment showed no significant difference in thrombotic (3.9% vs 5.2%, p=0.88) or hemorrhagic (3.9% vs 2.4%, p=0.47) complications compared to clopidogrel.
Why the study?
Clopidogrel resistance has led to the use of newer P2Y12 inhibitors like prasugrel to reduce thrombotic complications, but prasugrel may increase haemorrhagic complications in patients treated with flow diverters for intracranial aneurysms.
Does low-dose prasugrel compared to clopidogrel improve platelet response without increasing haemorrhagic complications in patients undergoing flow diverter treatment for intracranial aneurysms?
Cohort (n=225)
Does low-dose prasugrel compared to clopidogrel improve platelet response without increasing haemorrhagic complications in patients undergoing flow diverter treatment for intracranial aneurysms?
Absolute Event Rate: 3.9% vs 5.2%
p-value: p=0.88
Low-dose prasugrel is a safe alternative to clopidogrel for flow diverter treatment of intracranial aneurysms, significantly reducing the rate of P2Y12 non-responders without increasing haemorrhagic complications.
No takes yet. Share an insight, caveat, or question.
Low-dose prasugrel appears comparably safe; leaves open whether it reduces non-responders without added risk in randomized trials.
Flynn et al. (2023) conducted a cohort in Intracranial aneurysms (n=225). Prasugrel vs. Clopidogrel was evaluated on Thrombotic complications (p=0.88). Low-dose prasugrel for flow diverter treatment showed no significant difference in thrombotic (3.9% vs 5.2%, p=0.88) or hemorrhagic (3.9% vs 2.4%, p=0.47) complications compared to clopidogrel.